Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension

Ke Hao, Shaojie Peng, Aiqun Huang, Xiumei Hong, Yan Zhang, Xiaotao Zhao, Houxun Xing, Jianping Li, Alayne Ronnenberg, Xin Xu, Tianhua Niu, Xiping Xu

Research output: Contribution to journalArticle

Abstract

Objectives: Current treatment strategies for essential hypertension are effective only in a portion of patients. Many factors influence the therapeutic effect, including the status of left ventricular hypertrophy (LVH) and genetic variations. LVH influences the intensity of left ventricular depolarization and is a risk factor for many cardiovascular events independent of conventional predictors. The β3-adrenergic receptor (ADRB3) gene polymorphism is also associated with elevated blood pressure (BP) and cardiovascular disorders. In this study, we examined the impact of LVH (diagnosed by an electrocardiograph) and ADRB3 polymorphism on response to anti-hypertensive therapy. Methods: We treated a hypertensive cohort with benazepril for a period of 15 days, and evaluated the drug effect by BP drop (ΔBP). We performed standard ECG measurement on each subject and determined ADRB3 genotypes experimentally. Smoothing plots were first used to visualize the relationship, and additive models were fitted to investigate the role of LVH and ADRB3 polymorphism as well as their interactions with the treatment effect. Results: Electrocardiographic LVH was positively associated baseline BP, and negatively associated with ΔBP. The relationship was in a linear pattern. The association is greatly modified by ADRB3 genotype. In ADRB3 wildtype patients, the effect size increased, however, among ADRB3 mutant subjects, the association was attenuated and remained statistically non-significant. Conclusion: Our results suggested the predictive value of electrocardiographically diagnosed LVH to the anti-hypertensive treatment effectiveness, and pointed out the importance of gene-environment interaction. Our finding could have significant clinical implications to optimize the therapeutic dose range based on the ECG indexes.

Original languageEnglish (US)
Pages (from-to)293-301
Number of pages9
JournalJournal of Applied Research
Volume4
Issue number2
StatePublished - 2004
Externally publishedYes

Fingerprint

Left Ventricular Hypertrophy
Adrenergic Receptors
Hypertension
Blood Pressure
Electrocardiography
Antihypertensive Agents
Therapeutics
Genotype
Gene-Environment Interaction
Therapeutic Uses
Pharmaceutical Preparations
Genes

Keywords

  • ACE inhibitors
  • Electrocardiography
  • Genetic polymorphisms
  • Hypertension

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension. / Hao, Ke; Peng, Shaojie; Huang, Aiqun; Hong, Xiumei; Zhang, Yan; Zhao, Xiaotao; Xing, Houxun; Li, Jianping; Ronnenberg, Alayne; Xu, Xin; Niu, Tianhua; Xu, Xiping.

In: Journal of Applied Research, Vol. 4, No. 2, 2004, p. 293-301.

Research output: Contribution to journalArticle

Hao, K, Peng, S, Huang, A, Hong, X, Zhang, Y, Zhao, X, Xing, H, Li, J, Ronnenberg, A, Xu, X, Niu, T & Xu, X 2004, 'Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension', Journal of Applied Research, vol. 4, no. 2, pp. 293-301.
Hao, Ke ; Peng, Shaojie ; Huang, Aiqun ; Hong, Xiumei ; Zhang, Yan ; Zhao, Xiaotao ; Xing, Houxun ; Li, Jianping ; Ronnenberg, Alayne ; Xu, Xin ; Niu, Tianhua ; Xu, Xiping. / Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension. In: Journal of Applied Research. 2004 ; Vol. 4, No. 2. pp. 293-301.
@article{6f9996a44b50496e993c8d8117b9dd86,
title = "Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension",
abstract = "Objectives: Current treatment strategies for essential hypertension are effective only in a portion of patients. Many factors influence the therapeutic effect, including the status of left ventricular hypertrophy (LVH) and genetic variations. LVH influences the intensity of left ventricular depolarization and is a risk factor for many cardiovascular events independent of conventional predictors. The β3-adrenergic receptor (ADRB3) gene polymorphism is also associated with elevated blood pressure (BP) and cardiovascular disorders. In this study, we examined the impact of LVH (diagnosed by an electrocardiograph) and ADRB3 polymorphism on response to anti-hypertensive therapy. Methods: We treated a hypertensive cohort with benazepril for a period of 15 days, and evaluated the drug effect by BP drop (ΔBP). We performed standard ECG measurement on each subject and determined ADRB3 genotypes experimentally. Smoothing plots were first used to visualize the relationship, and additive models were fitted to investigate the role of LVH and ADRB3 polymorphism as well as their interactions with the treatment effect. Results: Electrocardiographic LVH was positively associated baseline BP, and negatively associated with ΔBP. The relationship was in a linear pattern. The association is greatly modified by ADRB3 genotype. In ADRB3 wildtype patients, the effect size increased, however, among ADRB3 mutant subjects, the association was attenuated and remained statistically non-significant. Conclusion: Our results suggested the predictive value of electrocardiographically diagnosed LVH to the anti-hypertensive treatment effectiveness, and pointed out the importance of gene-environment interaction. Our finding could have significant clinical implications to optimize the therapeutic dose range based on the ECG indexes.",
keywords = "ACE inhibitors, Electrocardiography, Genetic polymorphisms, Hypertension",
author = "Ke Hao and Shaojie Peng and Aiqun Huang and Xiumei Hong and Yan Zhang and Xiaotao Zhao and Houxun Xing and Jianping Li and Alayne Ronnenberg and Xin Xu and Tianhua Niu and Xiping Xu",
year = "2004",
language = "English (US)",
volume = "4",
pages = "293--301",
journal = "Journal of Applied Research",
issn = "1537-064X",
publisher = "The Journal of Applied Research",
number = "2",

}

TY - JOUR

T1 - Electrocardiographic left ventricular hypertrophy, β3 adrenergic receptor polymorphism and endpoint of ACEI treatment of hypertension

AU - Hao, Ke

AU - Peng, Shaojie

AU - Huang, Aiqun

AU - Hong, Xiumei

AU - Zhang, Yan

AU - Zhao, Xiaotao

AU - Xing, Houxun

AU - Li, Jianping

AU - Ronnenberg, Alayne

AU - Xu, Xin

AU - Niu, Tianhua

AU - Xu, Xiping

PY - 2004

Y1 - 2004

N2 - Objectives: Current treatment strategies for essential hypertension are effective only in a portion of patients. Many factors influence the therapeutic effect, including the status of left ventricular hypertrophy (LVH) and genetic variations. LVH influences the intensity of left ventricular depolarization and is a risk factor for many cardiovascular events independent of conventional predictors. The β3-adrenergic receptor (ADRB3) gene polymorphism is also associated with elevated blood pressure (BP) and cardiovascular disorders. In this study, we examined the impact of LVH (diagnosed by an electrocardiograph) and ADRB3 polymorphism on response to anti-hypertensive therapy. Methods: We treated a hypertensive cohort with benazepril for a period of 15 days, and evaluated the drug effect by BP drop (ΔBP). We performed standard ECG measurement on each subject and determined ADRB3 genotypes experimentally. Smoothing plots were first used to visualize the relationship, and additive models were fitted to investigate the role of LVH and ADRB3 polymorphism as well as their interactions with the treatment effect. Results: Electrocardiographic LVH was positively associated baseline BP, and negatively associated with ΔBP. The relationship was in a linear pattern. The association is greatly modified by ADRB3 genotype. In ADRB3 wildtype patients, the effect size increased, however, among ADRB3 mutant subjects, the association was attenuated and remained statistically non-significant. Conclusion: Our results suggested the predictive value of electrocardiographically diagnosed LVH to the anti-hypertensive treatment effectiveness, and pointed out the importance of gene-environment interaction. Our finding could have significant clinical implications to optimize the therapeutic dose range based on the ECG indexes.

AB - Objectives: Current treatment strategies for essential hypertension are effective only in a portion of patients. Many factors influence the therapeutic effect, including the status of left ventricular hypertrophy (LVH) and genetic variations. LVH influences the intensity of left ventricular depolarization and is a risk factor for many cardiovascular events independent of conventional predictors. The β3-adrenergic receptor (ADRB3) gene polymorphism is also associated with elevated blood pressure (BP) and cardiovascular disorders. In this study, we examined the impact of LVH (diagnosed by an electrocardiograph) and ADRB3 polymorphism on response to anti-hypertensive therapy. Methods: We treated a hypertensive cohort with benazepril for a period of 15 days, and evaluated the drug effect by BP drop (ΔBP). We performed standard ECG measurement on each subject and determined ADRB3 genotypes experimentally. Smoothing plots were first used to visualize the relationship, and additive models were fitted to investigate the role of LVH and ADRB3 polymorphism as well as their interactions with the treatment effect. Results: Electrocardiographic LVH was positively associated baseline BP, and negatively associated with ΔBP. The relationship was in a linear pattern. The association is greatly modified by ADRB3 genotype. In ADRB3 wildtype patients, the effect size increased, however, among ADRB3 mutant subjects, the association was attenuated and remained statistically non-significant. Conclusion: Our results suggested the predictive value of electrocardiographically diagnosed LVH to the anti-hypertensive treatment effectiveness, and pointed out the importance of gene-environment interaction. Our finding could have significant clinical implications to optimize the therapeutic dose range based on the ECG indexes.

KW - ACE inhibitors

KW - Electrocardiography

KW - Genetic polymorphisms

KW - Hypertension

UR - http://www.scopus.com/inward/record.url?scp=20844432877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20844432877&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:20844432877

VL - 4

SP - 293

EP - 301

JO - Journal of Applied Research

JF - Journal of Applied Research

SN - 1537-064X

IS - 2

ER -